Q1 EPS Estimates for Globus Medical Lowered by Roth Capital

Globus Medical, Inc. (NYSE:GMED) – Investment analysts at Roth Capital dropped their Q1 2025 earnings per share estimates for Globus Medical in a research report issued to clients and investors on Friday, February 21st. Roth Capital analyst J. Wittes now forecasts that the medical device company will earn $0.74 per share for the quarter, down from their prior forecast of $0.75. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Roth Capital also issued estimates for Globus Medical’s Q2 2025 earnings at $0.82 EPS, Q3 2025 earnings at $0.85 EPS, FY2025 earnings at $3.40 EPS, FY2026 earnings at $4.29 EPS and FY2027 earnings at $4.75 EPS.

GMED has been the topic of several other reports. StockNews.com upgraded Globus Medical from a “hold” rating to a “buy” rating in a report on Friday, February 14th. Roth Mkm increased their price target on Globus Medical from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 17th. BTIG Research increased their price target on Globus Medical from $87.00 to $91.00 and gave the stock a “buy” rating in a report on Thursday, December 12th. Piper Sandler increased their price target on Globus Medical from $80.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Finally, Bank of America upgraded Globus Medical from an “underperform” rating to a “neutral” rating and increased their price target for the stock from $80.00 to $97.00 in a report on Thursday, January 9th. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.91.

Globus Medical Stock Performance

Shares of NYSE GMED opened at $80.43 on Monday. The business’s 50 day moving average price is $86.72 and its 200-day moving average price is $79.16. Globus Medical has a fifty-two week low of $49.33 and a fifty-two week high of $94.93. The company has a market cap of $10.95 billion, a price-to-earnings ratio of 107.24, a PEG ratio of 1.61 and a beta of 1.19.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, February 20th. The medical device company reported $0.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.10. Globus Medical had a return on equity of 10.83% and a net margin of 4.09%. The business had revenue of $657.29 million for the quarter, compared to the consensus estimate of $646.19 million.

Insider Buying and Selling at Globus Medical

In other Globus Medical news, CFO Keith W. Pfeil sold 14,167 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $88.29, for a total transaction of $1,250,804.43. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Kelly Huller sold 2,500 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $87.00, for a total value of $217,500.00. The disclosure for this sale can be found here. Insiders own 18.54% of the company’s stock.

Institutional Trading of Globus Medical

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Burgundy Asset Management Ltd. boosted its position in Globus Medical by 1.7% during the 4th quarter. Burgundy Asset Management Ltd. now owns 2,618,108 shares of the medical device company’s stock valued at $216,544,000 after acquiring an additional 43,330 shares in the last quarter. PharVision Advisers LLC purchased a new stake in shares of Globus Medical during the 4th quarter valued at $339,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Globus Medical by 9.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 319,500 shares of the medical device company’s stock valued at $26,426,000 after purchasing an additional 28,330 shares during the last quarter. iSAM Funds UK Ltd purchased a new stake in shares of Globus Medical during the 4th quarter valued at $256,000. Finally, Vestal Point Capital LP purchased a new stake in shares of Globus Medical during the 4th quarter valued at $26,881,000. Institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.